UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 25, 2022

USANA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Utah

(State or other jurisdiction of incorporation)

001-35024 (Commission File No.) 87-0500306 (IRS Employer Identification No.)

3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Address of principal executive offices, Zip Code) Registrant's telephone number, including area code: (801) 954-7100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

1	Title of each class	Trading Symbol(s)	Name of each exchange on which registered	
(Common Stock, \$0.001 par value per share	USNA	New York Stock Exchange	

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On October 25, 2022, USANA Health Sciences, Inc. (the "Company" or "USANA") issued a press release announcing its financial results for the third quarter ended October 1, 2022. The release also announced that the Company will post a document titled "Management Commentary" on the Company's website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company's management team, before moving directly into questions and answers. A copy of the press release, and the Management Commentary, are furnished herewith as Exhibits to this Current Report on Form 8-K and are incorporated herein by reference. These documents will be posted on the Company's corporate website, www.usana.com.

The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

Item 7.01 Regulation FD Disclosure

The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)	Exhibits
Exhibit No.	Description
99.1	Press release issued by USANA Health Sciences, Inc. dated October 25, 2022 (furnished herewith).
99.2	Management Commentary provided by USANA Health Sciences, Inc. dated October 25, 2022 (furnished herewith).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

USANA HEALTH SCIENCES, INC.

By: <u>/s/ G. Douglas Hekking</u> G. Douglas Hekking, Chief Financial Officer

Date: October 25, 2022

Exhibit Index

Exhibit No.	Description
<u>99.1</u>	Press release issued by USANA Health Sciences, Inc. dated October 25, 2022 (furnished herewith).
<u>99.2</u>	Management Commentary provided by USANA Health Sciences, Inc. dated October 25, 2022 (furnished herewith).

USANA Health Sciences Reports Third Quarter Results

SALT LAKE CITY--(BUSINESS WIRE)--October 25, 2022--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended October 1, 2022.

Key Financial & Operating Results

- Third quarter net sales were \$233 million as compared with \$274 million during the third quarter of the prior year.
- Third quarter diluted EPS totaled \$0.78 versus \$1.36 during the third quarter of 2021.
- Company revises fiscal 2022 net sales and diluted EPS outlook to \$955 million to \$975 million and \$3.15 to \$3.40, respectively.

Q3 2022 Financial Performance

	Consolidated Results					
Net Sales	\$233 million	 -15% vs. prior-year quarter -9% constant currency vs. prior-year quarter -\$15 million YOY FX impact, or -6% -9% sequentially in constant currency 				
Diluted EPS	\$0.78	 -43% vs. prior-year quarter -22% sequentially Diluted shares of 19.3 million, -4% year-over-year 				
Active Customers	474,000	 -18% vs. prior-year quarter -15% sequentially 				

"The challenging operating environment in Asia Pacific and the strengthening U.S. dollar negatively affected our operating results in the third quarter," said Kevin Guest, Chief Executive Officer and Chairman of the Board. "COVID-related disruptions and challenging economic conditions resulting from those disruptions negatively impacted our results in several key Asia Pacific markets where city-wide lockdowns and other COVID restrictions persisted. This difficult operating environment has impacted our entire industry."

Guest continued, "While we remain committed to our long-term business strategy, our team is evaluating and executing several short-term initiatives to regain momentum in our business. These initiatives include new and modified incentives in various markets and regions to make our overall incentive offering more rewarding and attractive to our sales force. They also include more targeted, relevant in-person communications amongst our management team and Associate leaders, as well as accelerating our return to live sales force meetings and events in markets where that is possible. In that regard, in August we held a successful 30th Anniversary Global Convention in Salt Lake City. The four-day event attracted 4,000 in-person and more than 50,000 virtual attendees. In-person gatherings of this nature, as well as smaller more targeted gatherings, have been, and will continue to be, invaluable in generating momentum for our business. Finally, we continued to make progress on our digital strategy during the quarter by improving our consumer online shopping experience and will continue to execute our digital strategy going forward."

Q3 2022 Regional Results:

	Α	sia Pacific Region
Net Sales	\$183 million	 -17% vs. prior-year quarter -11% constant currency vs. prior-year quarter -13% constant currency sequentially 78% of consolidated net sales
Active Customers	362,000	 -18% vs. prior-year quarter -17% sequentially
	Asia	Pacific Sub-Regions
		Greater China
Net Sales	\$110 million	 -11% vs. prior-year quarter -6% constant currency vs. prior-year quarter
Active Customers	213,000	 -13% vs. prior-year quarter -23% sequentially
	I	North Asia
Net Sales	\$26 million	 -22% vs. prior-year quarter -10% constant currency vs. prior-year quarter
Active Customers	54,000	 -14% vs. prior-year quarter -5% sequentially
	Sou	Itheast Asia Pacific
Net Sales	\$47 million	 -27% vs. prior-year quarter -21% constant currency vs. prior-year quarter
Active Customers	95,000	 -29% vs. prior-year quarter -8% sequentially

	Americas and Europe Region					
Net Sales \$51 million		 -5% vs. prior-year quarter -4% constant currency vs. prior-year quarter +9% constant currency sequentially 22% of consolidated net sales Includes \$2.3 million of Q3 2022 sales contribution from recent acquisitions 				
Active Customers	112,000	 -16% vs. prior-year quarter -7 % sequentially 				

Balance Sheet and Share Repurchase Activity

The Company generated \$29 million in operating cash flow during the third quarter and ended the quarter with \$247 million in cash and cash equivalents, and debtfree. We did not repurchase shares during the quarter and, as of October 1, 2022, the Company had approximately \$83 million remaining under the share repurchase authorization.

Fiscal 2022 Outlook

The Company is revising its net sales and earnings per share outlook for fiscal year 2022 as follows:

Fiscal Year 2022 Outlook					
	Revised Range	Previous Range			
Consolidated Net	\$955 - \$975	\$1,015 - \$1,065			
Sales	million	million			
Diluted EPS	\$3.15 - \$3.40	\$3.85 - \$4.45			

"Third quarter top line results reflected the negative impact that macro- and local-economic factors had on our Active Customer counts in several of our key markets," said Doug Hekking, Chief Financial Officer. "Additionally, we experienced greater than expected downward pressure from the stronger U.S. dollar both on net sales and operating margins.

"We are adjusting our fiscal 2022 outlook to reflect the lower Active Customer base at the end of the third quarter, along with continued expectations of COVIDrelated, inflationary and economic challenges in many of our markets. The revised guidance also incorporates our expectations that margins will continue to be pressured in the short- to mid-term.

"Despite the near-term disruptions, we remain committed to achieving our long-term strategic initiatives. We believe these initiatives will position USANA to deliver sustainable net sales and EPS growth over the long-term. Over the short-term, we are actively evaluating and implementing actions to minimize the impact of the macro-operating environment on our financial performance. Our balance sheet remains debt-free and we expect to generate operating cash flow of approximately \$80 million in fiscal 2022."

Management Commentary Document and Conference Call

For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will hold a conference call and webcast to discuss today's announcement with investors on Wednesday, October 26, 2022 at 11:00 AM Eastern Time. **Investors may listen to the call by accessing USANA's website at http://ir.usana.com** The call will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.

Non-GAAP Financial Measures

The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP"). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, "Financial Results") are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates ("FX") and help facilitate period-to-period comparisons of the Company's Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.

About USANA

USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, and Italy. More information on USANA can be found at <u>www.usana.com</u>.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: uncertainty related to the magnitude, scope and duration of the impact of the COVID-19 pandemic ("COVID-19") to our business, operations and financial results; the further spread of, and regulatory measures or voluntary actions that may be put in place to limit the spread of, COVID-19 in the markets where we operate, including restrictions on business operations, shelter at home, or social distancing requirements; the potential for a resurgence of COVID-19 spread in any of our markets in the future; the impact of COVID-19 on the domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; regulatory risk in China in connection with the health products and direct selling business models; regulatory risk in the United States in connection with the direct selling business model; potential negative effects of deteriorating foreign and/or trade relations between the United States and China; potential negative effects from geopolitical relations and conflicts, including the Russia-Ukraine conflict; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; global economic conditions generally, including increasing inflationary pressure around the world and any negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model; adverse publicity risks globally; risks associated with our international expansion and operations; and uncertainty relating to the fluctuation in U.S. and other international currencies. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

USANA Health Sciences, Inc. Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

I-Oct-22 2-Oct-21 I-Oct-22 2-Oct-21 Net sales Cost of sales Gross profit Operating expenses: Associate incentives Solution ($180,740$) Solution ($180,60$) Solut		Quarter Ended Nine Months Ended
Cost of sales $\frac{46,560}{186,740}$ $50,715$ $147,460$ $165,380$ Operating expenses: Associate incentives $98,090$ $116,222$ $336,914$ $404,580$ Selling, general and administrative $66,020$ $66,645$ $201,204$ $210,518$ Earnings from operations $22,630$ $40,770$ $85,063$ $138,967$ Other income (expense), net 594 (420) 756 309 Income taxes $82,295$ $13,020$ $29,264$ $42,811$ NET EARNINGS $$$14,929$ $$27,330$ $$$56,555$ $96,185$ Earnings per share - diluted \$<0,78\$ 1.36 $$2.93$ $$4.68$ Weighted average shares outstanding - diluted \$<0,78\$ 1.36 $$2.93$ $$4.68$ Weighted average shares outstanding - diluted \$<0,78\$ 1.36 $$2.93$ $$4.68$ Weighted average shares outstanding - diluted \$<0,78\$ 1.36 $$2.93$ $$4.68$ Weighted average shares outstanding - diluted \$ $19,252$ $20,156$ $19,325$ $20,566$ \$ $52,246,879$		1-Oct-22 2-Oct-21 1-Oct-22 2-Oct-21
Cost of sales $\frac{46,560}{186,740}$ $50,715$ $147,460$ $165,380$ Operating expenses: Associate incentives $98,090$ $116,222$ $336,914$ $404,580$ Selling, general and administrative $66,020$ $66,645$ $201,204$ $210,518$ Earnings from operations $22,630$ $40,770$ $85,063$ $138,967$ Other income (expense), net 594 (420) 756 309 Income taxes $82,295$ $13,020$ $29,264$ $42,811$ NET EARNINGS $$$14,929$ $$27,330$ $$$56,555$ $96,185$ Earnings per share - diluted \$<0,78\$		
Gross profit 186,740 223,637 623,181 753,785 Operating expenses: Associate incentives 98,090 116,222 336,914 404,580 Solling, general and administrative 66,020 66,645 201,204 210,518 Earnings from operations 22,630 40,770 85,063 138,687 Other income (expense), net 594 (420) 756 309 Earnings before income taxes 23,224 40,350 85,819 138,996 Income taxes 8,295 13,020 29,264 42,811 NET EARNINGS \$ 14,929 \$ 27,330 \$ 56,555 \$ 96,185 Earnings per share - diluted \$ 0,78 \$ 1.36 \$ 2.93 \$ 4.68 Weighted average shares outstanding - diluted 19,252 20,156 19,325 20,566 USANA Health Sciences, Inc. Consolidated Balance Sheets (Unaudited) Unaudited) 19,252 20,156 19,325 20,566 Ass of As of 1-Oct-22 1-Jan-22 ASSETS Current Assets 5246,879 \$239,832 Inventories 67,278 98,318 Prepaid expenses and other current assets 26,997 2		
Operating expenses: Associate incentives 98,090 $116,222$ $336,914$ $404,580$ Selling, general and administrative $66,020$ $66,645$ $201,204$ $210,518$ Earnings from operations $22,630$ 40.770 $85,063$ $138,687$ Other income (expense), net 594 (420) 756 309 Earnings before income taxes $8,295$ $13,020$ $29,264$ $42,811$ NET EARNINGS \$ $14,929$ $27,330$ \$ $56,555$ $96,185$ Earnings per share - diluted \$ 0.78 \$ 1.36 \$ 2.93 \$ 4.68 Weighted average shares outstanding - $19,252$ $20,156$ $19,325$ $20,566$ USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited) $10,252$ $13,697$ $25,667$ As of As of Current Assets Cash and cash equivalents $52,6,997$ $26,997$		
Associate incentives 98,090 $116,222$ $336,914$ $404,580$ Selling, general and administrative $66,020$ $66,645$ $201,204$ $210,518$ Earnings from operations $22,630$ $40,770$ $85,063$ $138,687$ Other income (expense), net 594 (420) 756 309 Income taxes $8,295$ $13,020$ $29,264$ $42,811$ NET EARNINGS \$ 1.4929 \$ $27,330$ \$ $56,555$ $96,185$ Earnings per share - diluted \$ 0.78 \$ 1.36 \$ 2.93 \$ 4.68 Weighted average shares outstanding - $19,252$ $20,156$ $19,325$ $20,566$ USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited) As of As of As of As of Current Assets Cash and cash equivalents $5246,879$ $5239,832$ Inventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assets $32,158$ $30,442$		186,740 223,637 623,181 753,785
Selling, general and administrative $60,020$ $66,645$ $201,204$ $210,518$ Earnings from operations 594 (420) 756 309 Earnings before income taxes $23,224$ $40,350$ $85,819$ $138,996$ Income taxes $8,295$ $13,020$ $29,264$ $42,811$ NET EARNINGS \$ 0.78 \$ 1.36 \$ 2.93 \$ 4.68 Weighted average shares outstanding - $19,252$ $20,156$ $19,325$ $20,566$ USANA Health Sciences, Inc. Consolidated Balance Sheets $19,252$ $20,156$ $19,325$ $20,566$ Usand cash equivalents $5246,879$ \$ $239,832$ $110,402$ $17,278$ $89,8318$ Prepaid expenses and other current assets $26,997$ $26,967$ $26,967$ Total current assets $23,2158$ $30,442$ $26,977$ $26,967$ Property and equipment, net $95,228$ $101,780$ $57,400$ $57,894$ Goodwill 17,104 $17,668$ $114,929$ $555,60,63$ $557,740$ Ltabilities $57,400$ $57,894$ $5556,60,63$ $57,7,400$ $57,894$		
Earnings from operations $22,630 + 40,770 + 85,063 + 138,687$ Other income (expense), net $594 + (420) - 756 + 309$ Earnings before income taxes $594 + (420) - 756 + 309$ Income taxes $8,295 + 13,020 + 29,264 + 42,811 + 149,295 + 27,330 + 56,555 + 96,185$ NET EARNINGS \$ 14,9295 + 27,330 + 56,555 + 96,185 Earnings per share - diluted \$ 0.78 + 1.36 + 2.93 + 4.68 + 49,929 + 27,330 + 56,555 + 96,185 Weighted average shares outstanding - diluted 19,252 + 20,156 + 19,325 + 20,566 USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited) Current Assets 67,278 + 98,318 Cash and cash equivalents \$ 26,997 + 26,967 + 26,967 + 728 + 98,318 Prepaid expenses and other current assets 26,997 + 26,967 + 26,967 + 341,154 + 365,117 Property and equipment, net 95,228 + 101,780 + 30,442 + 26,979 + 23,183 + 30,442 + 23,158 + 30,442 + 3556,063 + 57,740 + 57,400 + 57,894 + 3556,063 + 57,740 + 57,400 + 57,894 + 3556,063 + 57,740 + 57,400 + 57,894 + 3556,063 + 57,740 + 57,400 + 57,894 + 3556,063 + 57,740 + 57,400 + 57,894 + 3556,063 + 57,740 + 55,84 + 143,217 + 4,322 + 58,84 + 160,790		
Other income (expense), net 594 (420) 756 309 Earnings before income taxes $23,224$ $40,350$ $85,819$ $138,996$ Income taxes $8,295$ $13,020$ $29,264$ $42,811$ NET EARNINGS \$ 14,929 \$ 27,330 \$ \$ 56,555 \$ 96,185 Earnings per share - diluted \$ 0.78 \$ 1.36 \$ 2.93 \$ 4.68 Weighted average shares outstanding - $19,252$ $20,156$ $19,325$ $20,566$ USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited) $8 \text{ of } As \text{ of } I-Oct-22 \text{ 1-Jan-22}$ Assets Cash and cash equivalents $5246,879 5239,832$ Inventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assets $32,158$ $30,442$ Deferred tax assets $13,019$ 4.839 Other assets $57,400$ $57,894$ Total assets $57,400$ $57,894$ Cash and cash equivalent, net $95,50,603$ $557,77,740$ LIABILITIES AND		
Earnings before income taxes $23,224$ $40,350$ $85,819$ $138,996$ Income taxes $8,295$ $13,020$ $29,264$ $42,811$ NET EARNINGS \$ 14,929 \$ 27,330 \$ 56,555 \$ 96,185 Earnings per share - diluted \$ 0.78 \$ 1.36 \$ 2.93 \$ 4.68 Weighted average shares outstanding - diluted 19,252 20,156 19,325 20,566 USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited) ASSETS $1-Oet-22$ 1-Jan-22 Current Assets $67,278$ 98,318 Prepaid expenses and other current assets $26,997$ 26,967 Total current assets $26,997$ 26,967 Total current assets $32,158$ 30,442 Deferred tax assets $57,400$ 57,894 Total assets $555,6,063$ \$577,740 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable \$ 10,362 \$ 13,508 Other assets $15,484$ 147,282 Total current liabilities $4,801$ 7,497 Other long-term liabilities $4,801$ 7,497 Other long-term liabilities $4,11,099$ 395,124	с .	
Income taxes $8,295$ $13,020$ $29,264$ $42,811$ NET EARNINGS $\overline{8}$ $14,929$ $\overline{8}$ $56,555$ $\overline{8}$ $96,185$ Earnings per share - diluted \$ 0.78 1.36 2.93 4.68 Weighted average shares outstanding - diluted 19,252 $20,156$ $19,325$ $20,566$ USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited) As of As of As of I-Oct-22 I-Jan-22 Assets Cash and cash equivalents $$246,879$ $$239,832$ Inventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assets Total current assets Total current assets Obter assets, net 32,158 $30,442$ Deferred tax assets Obter current Liabilities Total assets Stop,603 Current Liabilities Current Liabilities Obther current liabi		
NET EARNINGS $$ 14,929 $ 27,330 $ 56,555 $ 96,185$ Earnings per share - diluted\$ 0.78 \$ 1.36 \$ 2.93 \$ 4.68Weighted average shares outstanding - diluted19,252 20,156 19,325 20,566USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited)ASSETS $$ 1-Oct-22 1-Jan-22$ ASSETSCurrent AssetsCarl and cash equivalents\$ 246,879 \$239,832Inventories67,278 98,318Prepaid expenses and other current assets $26,997 26,967$ Total current assets $24,97,228 101,780$ Goodwill17,104 17,668Intangible assets, net $32,158 30,442$ Deferred tax assets $57,400 57,894$ Stockholders' EQUITYCurrent Liabilities $$ 10,362 $ 13,508$ Other current liabilities $$ 115,484 147,282$ Total current liabilities $$ 4,801 7,497$ Other long-term liabilities $$ 4,11,099 395,124$	0	
Earnings per share - diluted $\$ 0.78\$ 1.36\$ 2.93\$ 4.68$ Weighted average shares outstanding - diluted 19,252 20,156 19,325 20,566 USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited) As of As of 1-Oct-22 1-Jan-22 ASSETS Current Assets Cash and cash equivalents $\$246,879\$239,832$ Inventories 67,278 98,318 Prepaid expenses and other current assets 26,997 26,967 Total current assets 341,154 365,117 Property and equipment, net 95,228 101,780 Goodwill 17,104 17,668 Intangible assets, net 32,158 30,442 Deferred tax assets 57,400 57,894 Total assets $\$556,063\$577,740$ LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities 115,484 147,282 Total current liabilities 115,484 147,282 Total current liabilities 115,484 147,282 Total current liabilities 4,801 7,497 Other long-term liabilities 14,317 14,329 Stockholders' equity 411,099 395,124	Income taxes	
Weighted average shares outstanding - 19,252 20,156 19,325 20,566USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited)As of As of As of 1-Oct-22 1-Jan-22ASSETSCurrent AssetsCash and cash equivalents $$246,879$239,832$Inventories67,278 98,318Prepaid expenses and other current assets26,997 26,967Total current assets26,99726,967Total current assets341,154365,117Property and equipment, net95,22810,10417,668Intangible assets, net32,15830,442Deferred tax assets13,0194,839Other assets556,063$577,740LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts payable$ 10,362$ 13,508Other current liabilities115,484 147,282125,846 160,790Deferred tax liabilities115,484 147,282125,846 160,790Deferred tax liabilities14,317 14,329Stockholders' equity411,099 395,124$	NET EARNINGS	<u>\$ 14,929</u> \$ 27,330 \$ 56,555 \$ 96,185
Weighted average shares outstanding - 19,252 20,156 19,325 20,566USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited)As of As of As of 1-Oct-22 1-Jan-22ASSETSCurrent AssetsCash and cash equivalents $$246,879$239,832$ Inventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assets26,097 $26,967$ Total current assets $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill17,10417,668Intangible assets, net $32,158$ $30,442$ Deferred tax assets $57,400$ $57,894$ Total assets $5556,063$$577,740$ LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities $115,484$ Accounts payable\$ 10,362\$\$13,508Other current liabilities $115,484$ 141,099 $395,124$ Other long-term liabilities $141,099$ $395,124$ $411,099$ Stockholders' equity $411,099$ $395,124$		
Weighted average shares outstanding - 19,252 20,156 19,325 20,566USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited)As of As of As of 1-Oct-22 1-Jan-22ASSETSCurrent AssetsCash and cash equivalents $$246,879$239,832$ Inventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assets26,097 $26,967$ Total current assets $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill17,10417,668Intangible assets, net $32,158$ $30,442$ Deferred tax assets $57,400$ $57,894$ Total assets $5556,063$$577,740$ LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities $115,484$ Accounts payable\$ 10,362\$\$13,508Other current liabilities $115,484$ 141,099 $395,124$ Other long-term liabilities $141,099$ $395,124$ $411,099$ Stockholders' equity $411,099$ $395,124$		
diluted 19,252 20,156 19,325 20,566 USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited) As of As of 1-Oct-22 1-Jan-22 ASSETS Current Assets Cash and cash equivalents $$246,879$239,832$ Inventories 67,278 98,318 Prepaid expenses and other current assets $26,997$ 26,967 Total current assets $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill $17,104$ $17,668$ Intangible assets, net $32,158$ $30,442$ Deferred tax assets $57,400$ $57,894$ Total assets $57,400$ $57,894$ Total assets $5556,063$ $$577,740$ LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities $115,484$ $147,282$ Total current liabilities $115,484$ $147,282$ Total current liabilities $14,317$ $14,329$ Stockholders' equity $411,009$ $395,124$		\$ 0.78\$ 1.36 \$ 2.93\$ 4.68
USANA Health Sciences, Inc. Consolidated Balance Sheets (In thousands) (Unaudited)As of As of I-Oct-22 I-Jan-22ASSETSCurrent AssetsCash and cash equivalents $$246,879$239,832$ InventoriesInventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assetsTotal current assets $341,154$ $365,117$ Property and equipment, net $000000000000000000000000000000000000$	6 6	10.252 20.157 10.225 20.577
Consolidated Balance Sheets (In thousands) (Unaudited)As of As of I-Oct-22 I-Jan-22AssetsCurrent AssetsCash and cash equivalents $\$246,879\$239,832$ InventoriesInventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assetsProperty and equipment, net $95,228$ $101,780$ GoodwillProperty and equipment, net $95,228$ $101,780$ GoodwillProperty and equipment, net $95,228$ $101,780$ GoodwillOther assets $57,400$ $57,894$ $$556,063\$577,740$ CLABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts payable $\$$ $10,362\$$ $13,508$ Other current liabilities $115,484$ $147,282$ Total current liabilitiesAccounts nayable $\$$ $10,362\$$ $13,508$ Other current liabilities $4,801$ $125,846$ $160,790$ Deferred tax liabilities $4,801$ $14,317$ $14,329$ Stockholders' equity $\frac{411,099}{395,124}$ $4110,99$	diluted	19,252 20,156 19,325 20,566
In thousands) (Unaudited)As of As of I-Oct-22 1-Jan-22AssetsCurrent AssetsCash and cash equivalents $\$246,879\$239,832$ InventoriesInventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assets $26,997$ $26,967$ Total current assets $26,997$ $26,967$ Total current assets $21,154$ $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill $17,104$ $17,104$ $17,668$ Intangible assets, net $32,158$ $30,194$ As39Other assets $57,400$ $57,894$ S556,063 \$577,740CLABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts payable $\$$ $10,362$ \$ 13,508Other current liabilities $115,484$ $147,282$ Total current liabilities $125,846$ $160,790$ Deferred tax liabilities $48,01$ $7,497$ Other long-term liabilities $14,317$ $14,329$ Stockholders' equity $411,099$ $395,124$	USANA Health Scienc	es, Inc.
(Unaudited) As of As of 1-Oct-22 1-Jan-22 ASSETS Current Assets Cash and cash equivalents $$246,879$239,832$ Inventories $67,278$ 98,318 Prepaid expenses and other current assets $26,997$ 26,967 Total current assets $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill $17,104$ $17,668$ Intangible assets, net $32,158$ $30,442$ Deferred tax assets $13,019$ $4,839$ Other assets $57,400$ $57,894$ Total assets $57,400$ $57,894$ Total assets $\frac{5556,063}{5577,740}$ LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities $\frac{115,484}{147,282}$ Total current liabilities $\frac{115,484}{147,282}$ Total current liabilities $\frac{4,801}{7,497}$ Other long-term liabilities $\frac{4,801}{14,317}$ $\frac{7,497}{14,329}$ Stockholders' equity $\frac{411,099}{395,124}$	Consolidated Balance	Sheets
As of As of $1-Oct-22$ $1-Jan-22$ ASSETSCurrent AssetsCash and cash equivalents\$246,879 \$239,832 $67,278$ Inventories $67,278$ Prepaid expenses and other current assets $26,997$ $26,997$ $26,967$ $26,967$ Total current assets $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill $17,104$ $17,104$ $17,668$ Intangible assets, net $32,158$ $30,442$ Deferred tax assets $13,019$ $4,839$ Other assets $57,400$ $57,894$ $4005,77,894$ Current LiabilitiesAccounts payable\$10,362 \$13,508Other current liabilities $115,484$ $147,282$ Total current liabilities $48,01$ $7,497$ Other long-term liabilities $43,17$ $44,317$ $14,329$	(In thousands)	
I-Oct-22 1-Jan-22ASSETSCurrent AssetsCash and cash equivalents $$246,879 $239,832$ Inventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assets $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill $17,104$ $17,668$ Intangible assets, net $32,158$ $30,442$ Deferred tax assets $13,019$ $4,839$ Other assets $57,400$ $57,894$ Total assets $$556,063 $577,740$ LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities $115,484$ Accounts payable\$ 10,362 \$ 13,508Other current liabilities $115,484$ Itage and the second	(Unaudited)	
I-Oct-22 1-Jan-22ASSETSCurrent AssetsCash and cash equivalents $$246,879 $239,832$ Inventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assets $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill $17,104$ $17,668$ Intangible assets, net $32,158$ $30,442$ Deferred tax assets $13,019$ $4,839$ Other assets $57,400$ $57,894$ Total assets $$556,063 $577,740$ LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities $115,484$ Accounts payable\$ 10,362 \$ 13,508Other current liabilities $115,484$ Itage and the second		
ASSETSCurrent AssetsCash and cash equivalents $$246,879$239,832$ Inventories $67,278$ Prepaid expenses and other current assets $26,997$ 26,967 $26,967$ Total current assets $341,154$ 365,117Property and equipment, net $95,228$ 10,780Goodwill $17,104$ 17,104 $17,668$ Intangible assets, net $32,158$ 30,442Deferred tax assets $13,019$ 4,839Other assets $57,400$ $57,894$ Total assets $$556,063$$577,740$ LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities $115,484$ Accounts payable\$10,362\$\$13,508Other current liabilities $125,846$ 160,790Deferred tax liabilities $4,801$ 7,497Other long-term liabilities $14,317$ 14,329Stockholders' equity $411,099$ 395,124		As of As of
Current AssetsCurrent AssetsCash and cash equivalents $\$246,879\$239,832$ Inventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assets $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill $17,104$ $17,668$ Intangible assets, net $32,158$ $30,442$ Deferred tax assets $13,019$ $4,839$ Other assets $57,400$ $57,894$ Total assets $\$556,063\$577,740$ LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities $115,484$ Accounts payable $\$10,362\$13,508$ Other current liabilities $125,846$ Iotal current liabilities $125,846$ Iotal current liabilities $14,317$ Idage $411,099$ Stockholders' equity $411,099$ 395,124		1-Oct-22 1-Jan-22
Cash and cash equivalents \$246,879\$239,832 Inventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assets $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill $17,104$ $17,668$ Intangible assets, net $32,158$ $30,442$ Deferred tax assets $13,019$ $4,839$ Other assets $57,400$ $57,894$ Total assets $$556,063$ $$577,740$ LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities $115,484$ $147,282$ Total current liabilities $115,484$ $147,282$ Total current liabilities $125,846$ $160,790$ Deferred tax liabilities $4,801$ $7,497$ 0 ther long-term liabilities $14,317$ $14,329$ Stockholders' equity $411,099$ $395,124$ $200,5124$ $200,5124$	ASSETS	
Inventories $67,278$ $98,318$ Prepaid expenses and other current assets $26,997$ $26,967$ Total current assets $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill $17,104$ $17,668$ Intangible assets, net $32,158$ $30,442$ Deferred tax assets $13,019$ $4,839$ Other assets $57,400$ $57,894$ Total assets $$556,063$ $$577,740$ LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable \$ 10,362 \$ 13,508 Other current liabilities $115,484$ $147,282$ Total current liabilities $125,846$ $160,790$ Deferred tax liabilities $4,801$ $7,497$ Other long-term liabilities $14,317$ $14,329$ Stockholders' equity $411,099$ $395,124$	Current Assets	
Prepaid expenses and other current assets $26,997$ $26,967$ Total current assets $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill $17,104$ $17,668$ Intangible assets, net $32,158$ $30,442$ Deferred tax assets $13,019$ $4,839$ Other assets $57,400$ $57,894$ Total assets $$556,063 \$577,740$ LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities $115,484$ $147,282$ Total current liabilities $115,484$ $147,282$ Total current liabilities $125,846$ $160,790$ Deferred tax liabilities $4,801$ $7,497$ Other long-term liabilities $14,317$ $14,329$ Stockholders' equity $411,099$ $395,124$	Cash and cash equivalents	\$246,879 \$239,832
Total current assets $341,154$ $365,117$ Property and equipment, net $95,228$ $101,780$ Goodwill $17,104$ $17,668$ Intangible assets, net $32,158$ $30,442$ Deferred tax assets $13,019$ $4,839$ Other assets $57,400$ $57,894$ Total assets $$556,063$ $$577,740$ LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable \$ 10,362 \$ 13,508 Other current liabilities $115,484$ $147,282$ Total current liabilities $125,846$ $160,790$ Deferred tax liabilities $4,801$ $7,497$ Other long-term liabilities $14,317$ $14,329$ Stockholders' equity $411,099$ $395,124$	Inventories	67,278 98,318
Property and equipment, net 95,228 101,780 Goodwill 17,104 17,668 Intangible assets, net 32,158 30,442 Deferred tax assets 13,019 4,839 Other assets $57,400$ $57,894$ Total assets \$556,063 \$577,740 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable \$ 10,362 \$ 13,508 Other current liabilities 115,484 147,282 Total current liabilities 125,846 160,790 Deferred tax liabilities 4,801 7,497 Other long-term liabilities 14,317 14,329 Stockholders' equity $411,099$ 395,124	Prepaid expenses and other current assets	26,997 26,967
Goodwill 17,104 17,668 Intangible assets, net 32,158 30,442 Deferred tax assets 13,019 4,839 Other assets $57,400$ $57,894$ Total assets \$556,063 \$577,740 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable \$ 10,362 \$ 13,508 Other current liabilities 115,484 147,282 Total current liabilities 125,846 160,790 Deferred tax liabilities 4,801 7,497 Other long-term liabilities 14,317 14,329 Stockholders' equity $411,099$ 395,124	Total current assets	341,154 365,117
Goodwill 17,104 17,668 Intangible assets, net 32,158 30,442 Deferred tax assets 13,019 4,839 Other assets $57,400$ $57,894$ Total assets \$556,063 \$577,740 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable \$ 10,362 \$ 13,508 Other current liabilities 115,484 147,282 Total current liabilities 125,846 160,790 Deferred tax liabilities 4,801 7,497 Other long-term liabilities 14,317 14,329 Stockholders' equity $411,099$ 395,124		
Intangible assets, net $32,158$ $30,442$ Deferred tax assets $13,019$ $4,839$ Other assets $57,400$ $57,894$ Total assets \$556,063 \$577,740 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable \$ 10,362 \$ 13,508 Other current liabilities 115,484 147,282 Total current liabilities 125,846 160,790 Deferred tax liabilities 4,801 7,497 Other long-term liabilities 14,317 14,329 Stockholders' equity $411,099$ $395,124$		
Deferred tax assets $13,019$ $4,839$ Other assets $57,400$ $57,894$ Total assets $\$556,063$ $\$577,740$ LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts payable $\$$ $10,362$ $\$$ Other current liabilities $115,484$ $147,282$ Total current liabilities $125,846$ $160,790$ Deferred tax liabilities $4,801$ $7,497$ Other long-term liabilities $14,317$ $14,329$ Stockholders' equity $411,099$ $395,124$		
Other assets $57,400$ $57,894$ \$556,063 \$577,740 LIABILITIES AND STOCKHOLDERS' EQUITY Current LiabilitiesAccounts payable\$ 10,362 \$ 13,508Other current liabilities $115,484$ $147,282$ Total current liabilities $125,846$ $160,790$ Deferred tax liabilities $4,801$ $7,497$ Other long-term liabilities $14,317$ $14,329$ Stockholders' equity $411,099$ $395,124$	- · ·	· · ·
Total assets\$556,063\$577,740LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts payable\$ 10,362\$ 13,508Other current liabilities115,484 147,282Total current liabilities125,846 160,790Deferred tax liabilities4,801 7,497Other long-term liabilities14,317 14,329Stockholders' equity411,099 395,124		
Total asses LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities \$ 10,362 \$ 13,508 Other current liabilities \$ 115,484 147,282 Total current liabilities \$ 125,846 160,790 Deferred tax liabilities \$ 14,317 14,329 Stockholders' equity \$ 411,099 395,124	Other assets	
Current LiabilitiesAccounts payable\$ 10,362 \$ 13,508Other current liabilities115,484 147,282Total current liabilities125,846 160,790Deferred tax liabilities4,801 7,497Other long-term liabilities14,317 14,329Stockholders' equity411,099 395,124	Total assets	\$556,063 \$577,740
Current LiabilitiesAccounts payable\$ 10,362 \$ 13,508Other current liabilities115,484 147,282Total current liabilities125,846 160,790Deferred tax liabilities4,801 7,497Other long-term liabilities14,317 14,329Stockholders' equity411,099 395,124		
Accounts payable \$ 10,362 \$ 13,508 Other current liabilities 115,484 147,282 Total current liabilities 125,846 160,790 Deferred tax liabilities 4,801 7,497 Other long-term liabilities 14,317 14,329 Stockholders' equity 411,099 395,124	LIABILITIES AND STOCKHOLDERS' I	EQUITY
Other current liabilities115,484147,282Total current liabilities125,846160,790Deferred tax liabilities4,8017,497Other long-term liabilities14,31714,329Stockholders' equity411,099395,124		
Total current liabilities125,846160,790Deferred tax liabilities4,8017,497Other long-term liabilities14,31714,329Stockholders' equity411,099395,124	Accounts payable	
Deferred tax liabilities 4,801 7,497 Other long-term liabilities 14,317 14,329 Stockholders' equity 411,099 395,124		
Other long-term liabilities 14,317 14,329 Stockholders' equity 411,099 395,124	Total current liabilities	125,846 160,790
Other long-term liabilities 14,317 14,329 Stockholders' equity 411,099 395,124		
Stockholders' equity <u>411,099_395,124</u>		
	Other long-term liabilities	14,317 14,329
Total liabilities and stockholders' equity \$556,063 \$577,740	Stockholders' equity	
	Total liabilities and stockholders' equ	nity <u>\$556,063 \$577,740</u>

USANA Health Sciences, Inc. Sales by Region (In thousands) (Unaudited)

Quarter Ended

	October	1, 2022	October 2	2, 2021	Change from	prior year	Currency impact on	
Asia Pacific								
Greater China	\$109,682	47.0%	\$123,235	44.9%	\$ (13,553)	(11.0%)	\$ (6,199)	(6.0%)
Southeast Asia Pacific	47,308	20.3%	64,570	23.5%	(17,262)	(26.7%)	(3,969)	(20.6%)
North Asia	25,667	11.0%	33,068	12.1%	(7,401)	(22.4%)	(4,006)	(10.3%)
Asia Pacific Total	182,657	78.3%	220,873	80.5%	(38,216)	(17.3%)	(14,174)	(10.9%)
Americas and Europe	50,643	21.7%	53,479	19.5%	(2,836)	(5.3%)	(875)	(3.7%)
	\$233,300	100.0%	\$274,352	100.0%	\$ (41,052)	(15.0%)	\$ (15,049)	(9.5%)

Active Associates by Region⁽¹⁾

(Unaudited)

		As	of	
	October	1, 2022	October	2, 2021
Asia Pacific				
Greater China	73,000	32.5%	81,000	29.8%
Southeast Asia Pacific	68,000	30.2%	90,000	33.1%
North Asia	34,000	15.1%	39,000	14.3%
Asia Pacific				
Total	175,000	77.8%	210,000	77.2%
Americas and Europe	50,000	22.2%	62,000	22.8%
	225,000	100.0%	272,000	100.0%

Active Preferred Customers by Region⁽²⁾

(Unaudited)

		As	of	
	October	1, 2022	October	2, 2021
Asia Pacific				
Greater China	140,000	56.2%	165,000	54.3%
Southeast Asia Pacific	27,000	10.9%	44,000	14.4%
North Asia	20,000	8.0%	24,000	7.9%
Asia Pacific Total	187,000	75.1%	233,000	76.6%
Americas and Europe	62,000	24.9%	71,000	23.4%
	249,000	100.0%	304,000	100.0%

(1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.

(2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

Contacts

Investor contact: Andrew Masuda Investor Relations (801) 954-7201 investor.relations@usanainc.com

Media contact: Dan Macuga Public Relations (801) 954-7280



USANA Health Sciences, Inc.

Q3 2022 Management Commentary

Key Financial & Operating Results

- Third quarter net sales were \$233 million as compared with \$274 million during the third quarter of the prior year.
- Third quarter diluted EPS totaled \$0.78 versus \$1.36 during the third quarter of 2021.
- Company revises fiscal 2022 net sales and diluted EPS outlook to \$955 million to \$975 million and \$3.15 to \$3.40, respectively.

Overview

Third quarter operating results were primarily affected by a more challenging than anticipated operating environment in Asia Pacific. A strengthening U.S. dollar also negatively impacted net sales by roughly 6%. Despite these challenges, operating cash flow generation in the quarter was \$29 million.

COVID-related disruptions in several markets in Asia Pacific persisted throughout the quarter and negatively affected our sales momentum and Active Customer counts. Consumer sentiment in this region also became more challenging during the quarter, which we believe is attributable largely to increasing inflationary pressure on consumers in many of our markets in this region.

Operationally, material and labor costs continued to rise, which weighed on our margins and profitability during the third quarter. The stronger U.S. dollar also contributed to margin compression during the period. We are working to better align our cost structure with current and expected sales performance while continuing to invest in select strategic initiatives that we believe are essential to position USANA to return to long-term growth.

Despite a challenging environment, we continued to make progress on our digital strategy through various initiatives. We successfully launched our updated onboarding program across all markets. We also rolled out new features and updates to our China shopping app as part of our commitment to provide our customers with the best overall shopping experience.

October 25, 2022

For the remainder of fiscal 2022, the operating environment in many of our markets remains unpredictable. We entered the fourth quarter with a lower than anticipated number of Active Customers, which we expect to pressure our results for the quarter. As such, we've adjusted our fiscal 2022 net sales and earnings per share outlook accordingly.

We are evaluating and executing several short-term initiatives to regain momentum in our business, including 1) new and modified incentives in various markets and regions to make our overall incentive offering more rewarding and attractive to our sales force; 2) more targeted, relevant in-person communications amongst our management team and Associate leaders; and 3) accelerating our return to live sales force meetings and events in markets where that is possible.

Although we believe these new incentives provide an attractive opportunity to encourage engagement from our sales force, the benefit to net sales and Active Customer counts from these incentives is anticipated to build steadily over time. We plan to introduce these incentives and programs during the latter part of the fourth quarter of 2022 through the first quarter of 2023. We believe that these efforts, combined with further assessment of our promotional strategy, will begin to generate momentum in the year ahead. We remain confident in the overall health of our business and believe that successful execution on our strategic initiatives will position USANA to return to long-term growth.

	Consolidated Results				
Net Sales	\$233 million	 -15% vs. prior-year quarter -9% constant currency vs. prior-year quarter -\$15 million YOY FX impact, or -6% -9% sequentially in constant currency 			
Diluted EPS	\$0.78	 -43% vs. prior-year quarter -22% sequentially Diluted shares of 19.3 million, -4% year-over-year 			
Active Customers	474,000	•-18% vs. prior-year quarter •-15% sequentially			

Balance Sheet and Share Repurchase Activity

We generated \$29 million in operating cash flow during the third quarter and ended the quarter with \$247 million in cash and cash equivalents, and debt-free. We did not repurchase shares during the quarter and, as of October 1, 2022, the Company had approximately \$83 million remaining under the share repurchase authorization.

Quarterly Income Statement Discussion

Gross margin decreased 150 basis points from the prior year to 80.0% of net sales. The decrease can be attributed to increased material and wage costs, the negative impact of currency exchange rates, higher inventory valuation adjustments and the loss of leverage on fixed-period costs due to lower net sales. Favorable changes in geographic sales mix partly offset these cost pressures.

Associate Incentives decreased 40 basis points from the prior year to 42.0% of net sales. The modest decrease reflects lower incentive and promotional expenses due lower net sales in the current-year quarter.

Selling, General and Administrative expenses increased 400 basis points from the prior year to 28.3% as a percentage of net sales. The relative increase is largely due to a loss of leverage on lower year-over-year net sales and costs related to our 30th Anniversary Convention where we had 4,000 in person attendees and more than 50,000 participating virtually. On an absolute basis, SG&A expenses decreased \$0.6 million compared to the prior year.



The effective tax rate increased to 35.7% from the 32.3% reported in the prior-year quarter, largely due to the mix of taxable income by market and a true up to the year-to-date effective tax rate estimates.

Regional Financial Results

Asia Pacific Region			
Net Sales	\$183 million	 3 million -17% vs. prior-year quarter -11% constant currency vs. prior-year quarter -13% constant currency sequentially 	
Active Customers	362,000	 •78% of consolidated net sales •-18% vs. prior-year quarter •-17% sequentially 	

		Asia Pacific Sub-Regions			
Greater China					
Net Sales	\$110 million •-11% vs. prior-year quarter •-6% constant currency vs. prior-year quarter				
Active Customers	213,000	•-13% vs. prior-year quarter •-23% sequentially			
		North Asia			
Net Sales	\$26 million	 -22% vs. prior-year quarter -10% constant currency vs. prior-year quarter 			
Active Customers	54,000	•-14% vs. prior-year quarter •-5% sequentially			
		Southeast Asia Pacific			
Net Sales	\$47 million	 -27% vs. prior-year quarter -21% constant currency vs. prior-year quarter 			
Active Customers	95,000	•-29% vs. prior-year quarter •-8% sequentially			

4

<u>Greater China:</u> Net sales and local currency sales in mainland China decreased 11% and 6% year-over-year, respectively, while Active Customers in this market were lower by 14%. COVID-related disruptions, including area-wide lockdowns, continued to negatively impact our business during the quarter. Sequentially, net sales and local currency sales in mainland China decreased 24% and 22%, respectively, while Active Customers declined 25%, due, in part, to the absence of promotional activity compared to the second quarter of 2022. We continue to believe in the significant and attractive long-term growth opportunity China presents.

North Asia: Net sales and local currency sales in South Korea decreased 22% and 10% year-over-year, respectively. This market continued to experience COVIDrelated disruptions, albeit to a lesser extent than mainland China. On a sequential basis, net sales and local currency sales declined 11% and 5%, respectively, due, in part, to the absence of promotional activity compared to the second quarter of 2022.

Southeast Asia Pacific: Several markets in this sub-region remain impacted by COVID-related restrictions and lockdowns. Additionally, consumer sentiment and purchasing behavior continues to be influenced by inflationary pressures and concerns around a slowdown in local economies. Local currency sales and Active Customers in Malaysia declined 29% and 40% year-over-year, respectively. Sequentially, local currency sales decreased 3% and Active Customers declined 18%. The Philippines reported local currency sales and Active Customer declines of 23% and 27%, respectively. On a sequential basis, local currency sales grew 15% and Active Customers declined 3%.

Americas and Europe Region				
Net Sales	······································			
		•-4% constant currency vs. prior-year quarter		
		•+9% constant currency sequentially		
		•22% of consolidated net sales		
		 Includes \$2.3 million of Q3 2022 sales contribution from recent acquisitions 		
Active Customers	112,000	•-16% vs. prior-year quarter		
		•-7 % sequentially		

Americas and Europe Region: Despite a 12% year-over-year decline in Active Customers in the United States, net sales were flat year-over-year and increased 10% sequentially, due to sales from our 30th Anniversary Convention. Net sales and local currency sales in Canada declined 17% and 14% year-over-year, respectively.

Outlook and 2022 Operating Strategy

We are revising our consolidated net sales and earnings per share outlook for fiscal year 2022 as follows:

Fiscal Year 2022 Outlook			
	Revised Range	Previous Range	
Consolidated Net Sales	\$955 - \$975 million	\$1,015 - \$1,065 million	
Diluted EPS	\$3.15 - \$3.40	\$3.85 - \$4.45	

Our revised outlook for the year reflects:

- An unfavorable currency exchange rate impact on net sales of approximately \$52 million (previously \$40 million) ٠
- An operating margin in the range of 9.8% and 10.4% (previously between 11% and 12%) •
- An annual effective tax rate between 34% and 35% (previously 33.5%) An annualized diluted share count of 19.3 million (unchanged) • ٠

6

Our revised fiscal 2022 outlook reflects the lower Active Customer base at the end of the third quarter, along with continued expectations of COVID-related, inflationary and economic challenges in many of our markets. The revised guidance also incorporates our expectations that margins will continue to be pressured in the short- to mid-term.

We remain committed to our long-term strategic growth objectives, including: (1) enhancing the digital experience for our customers to improve the overall online shopping experience; (2) improving Associate onboarding and training to help drive and sustain customer growth; (3) exploring additional promotional and incentive offerings on a market-specific basis; (4) driving growth in our China market, which includes launching experience centers to help facilitate our strategic growth plan for this key market and; (5) pursuing accretive business development opportunities.

Kevin Guest CEO

Douglas Hekking CFO This Management Commentary contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: uncertainty related to the magnitude, scope and duration of the impact of the COVID-19 pandemic ("COVID-19") to our business, operations and financial results; the further spread of, and regulatory measures or voluntary actions that may be put in place to limit the spread of, COVID-19 in the markets where we operate, including restrictions on business operations, shelter at home, or social distancing requirements; the potential for a resurgence of COVID-19 spread in any of our markets in the future; the impact of COVID-19 on the domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; regulatory risk in China in connection with the health products and direct selling business models; regulatory risk in the United States in connection with the direct selling business model; potential negative effects of deteriorating foreign and/or trade relations between the United States and China; potential negative effects from geopolitical relations and conflicts, including the Russia-Ukraine conflict; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; global economic conditions generally, including increasing inflationary pressure around the world and any negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model; adverse publicity risks globally; risks associated with our international expansion and operations; and uncertainty relating to the fluctuation in U.S. and other international currencies. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

Non-GAAP Financial Measures

The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP"). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, "Financial Results") are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates ("FX") and help facilitate period-to-period comparisons of the Company's Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.

Investor contact:

Media contact:

Andrew Masuda Investor Relations (801) 954-7210 investor.relations@usanainc.com

Dan Macuga Public Relations 801-954-7280

9